<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tepotinib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tepotinib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tepotinib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="130726" href="/d/html/130726.html" rel="external">see "Tepotinib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55546137"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Tepmetko</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56352781"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Tepmetko</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F55466203"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, MET Inhibitor;</li>
<li>
                        Antineoplastic Agent, Tyrosine Kinase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F55487489"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Select patients for treatment based on the presence of mesenchymal-epithelial transition (MET<i>) </i>exon 14 skipping alterations in tumor specimen (preferred) or plasma.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3ac928cc-a5fe-47d5-847f-e5abed320440">Non–small cell lung cancer, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Non–small cell lung cancer, metastatic: Oral:</b> 450 mg once daily until disease progression or unacceptable toxicity.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i> If a dose is missed, do not make it up if it is within 8 hours of the next scheduled dose. If vomiting occurs after administering a dose, administer the next dose at the scheduled time.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F55487491"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Kidney function estimated by Cockcroft-Gault equation.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: There is no dosage adjustment provided in the manufacturer's labeling (has not been established).</p></div>
<div class="block doha drugH1Div" id="F55487492"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment at treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild or moderate impairment (Child-Pugh class A or B): </i>No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe impairment (Child-Pugh class C):</i> There is no dosage adjustment provided in the manufacturer's labeling (has not been established).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">The recommended tepotinib dose reduction for adverse reactions is 225 mg once daily.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:center;">
<b>Recommended Tepotinib Dosage Modification for Hepatotoxicity </b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Adverse reaction </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Severity </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Tepotinib dose modification</b></p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Increased ALT and/or AST <b>without</b> increased total bilirubin</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold tepotinib until recovery to baseline ALT and/or AST. If recovered to baseline within 7 days, then resume tepotinib at the same dose; otherwise resume tepotinib at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue tepotinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Increased ALT and/or AST <b>with</b> increased total bilirubin (in the absence of cholestasis or hemolysis)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">ALT and/or AST &gt;3 times ULN with total bilirubin &gt;2 times ULN</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue tepotinib.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Increased total bilirubin <b>without</b> concurrent increased ALT and/or AST</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold tepotinib until recovery to baseline bilirubin. If recovered to baseline within 7 days, then resume tepotinib at a reduced dose; otherwise permanently discontinue tepotinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue tepotinib.</p></td></tr></tbody></table></div>
<div class="block dot drugH1Div" id="F55487494"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Recommended Tepotinib Dosage Reduction Level</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Initial (usual) dose</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">450 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">First dose reduction level</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">225 mg once daily</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:center;">Permanently discontinue tepotinib if unable to tolerate 225 mg once daily.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Recommended Tepotinib Dosage Modification for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">Adverse reaction</p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">Severity</p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">Tepotinib dose modification</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Interstitial lung disease (ILD)/pneumonitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Any</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold tepotinib if ILD is suspected. Permanently discontinue tepotinib if ILD is confirmed.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Other adverse reactions</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Maintain tepotinib dose level. If adverse reaction is intolerable, consider withholding tepotinib until adverse reaction is resolved, then resume tepotinib at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold tepotinib until adverse reaction is resolved, then resume tepotinib at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue tepotinib.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F55487490"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F56026887"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hepatotoxicity, including <b>increased serum alanine aminotransferase </b>(ALT), and <b>increased serum aspartate aminotransferase </b>(AST), has commonly been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32469185']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32469185'])">Ref</a></span>). <b>Hepatic failure</b> has been reported rarely. Depending on severity, therapy interruption or dose modification may be warranted, including permanent drug discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; median time to onset of ≥ grade 3 elevated ALT/AST was 30 days (range: 1 to 178 days).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Peripheral edema</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral edema</b> is commonly observed, including ≥ grade 3 events. Depending on severity, therapy interruption or dose modification may be warranted, including permanent discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32469185']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32469185'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pulmonary toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Interstitial pulmonary disease</b> (ILD)/<b>pneumonitis</b>, potentially life-threatening, has occurred, including rare ≥ grade 3 events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32469185']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32469185'])">Ref</a></span>). Symptoms of ILD/pneumonitis typically present as cough, dyspnea, and fever; permanent discontinuation is warranted if ILD/pneumonitis is confirmed.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F55469168"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (4% to 70%; including peripheral edema)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum albumin (76%), decreased serum sodium (31%), increased amylase (23%), increased gamma-glutamyl transferase (24%), increased serum potassium (25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (16%), constipation (16%), decreased appetite (16%), diarrhea (26%), increased serum lipase (18%), nausea (27%), vomiting (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (27%; grades 3/4: 2%), leukopenia (23%; grades 3/4: &lt;1%), lymphocytopenia (48%; grades 3/4: 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (44%), increased serum alkaline phosphatase (50%), increased serum aspartate aminotransferase (35%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (2% to 24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (55%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (15%), dyspnea (4% to 20%), pleural effusion (7% to 13%), pneumonia (5% to 11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Pulmonary embolism (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (&lt;10%), skin rash (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (&lt;10%), headache (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pulmonary disease (&lt;10%), pneumonitis (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (&lt;10%), physical health deterioration (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hepatic: Hepatic failure</p></div>
<div class="block coi drugH1Div" id="F55463741"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to tepotinib or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F55487474"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Mesenchymal-epithelial transition (MET) alterations: Select patients for treatment based on the presence of MET exon 14 skipping alterations in plasma or tumor specimens. Tumor biopsy is preferred; plasma specimen is recommended only when tumor biopsy cannot be obtained. If an alteration is not detected in a plasma specimen, re-evaluate the feasibility of biopsy for tumor tissue testing.</p></div>
<div class="block foc drugH1Div" id="F55546138"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tepmetko: 225 mg</p></div>
<div class="block geq drugH1Div" id="F55546136"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F55670733"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Tepmetko Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">225 mg (per each): $488.46</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56352782"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tepmetko: 225 mg</p></div>
<div class="block adm drugH1Div" id="F55487495"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with food at approximately the same time each day. Swallow whole; do not chew, crush, or split the tablets. Tablets may be dispersed in a glass of noncarbonated water (30 mL); do not use other liquids. Stir without crushing until tablet is in small pieces (tablet will not completely dissolve). Administer immediately or within 1 hour; do not chew tablet pieces. Rinse glass with an additional 30 mL and drink immediately to ensure remaining residue and full dose is administered.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>NG tube:</b> Tablets may be dispersed in a glass of noncarbonated water (30 mL); do not use other liquids. Stir without crushing until tablet is in small pieces (tablet will not completely dissolve). Administer immediately or within 1 hour via NG tube (≥8 French gauge); immediately rinse twice with 30 mL each time to ensure remaining residue and full dose is administered.</p></div>
<div class="block hazard drugH1Div" id="F55487476"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Tepotinib may cause teratogenicity and reproductive toxicity.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F55463740"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Non–small cell lung cancer, metastatic:</b> Treatment of metastatic non–small cell lung cancer in adults harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.</p></div>
<div class="block mst drugH1Div" id="F55487465"><span class="drugH1">Medication Safety Issues</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Sound-alike/look-alike issues:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Tepotinib may be confused with capmatinib, crizotinib, ertlotinib, nilotinib, talazoparib, tofacitinib, trametinib, tucatinib.</p>
<p style="text-indent:-2em;margin-left:4em;">Tepmetko may be confused with Tabrecta.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>High alert medication:</b></p>
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) included among its lists of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
<div class="block cyt drugH1Div" id="F55504457"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> P-glycoprotein/ABCB1</p></div>
<div class="block dri drugH1Div" id="F55504454"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: If combined, administer the P-gp inhibitor simultaneously with, or after, the dose of afatinib. Monitor closely for signs and symptoms of afatinib toxicity and if the combination is not tolerated, reduce the afatinib dose by 10 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Berotralstat.  Management: Decrease the berotralstat dose to 110 mg daily when combined with P-glycoprotein (P-gp) inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: This combination is often contraindicated, but combined use may be permitted with dose adjustment and monitoring. Recommendations vary based on brand, indication, use of CYP3A4 inhibitors, and hepatic/renal function. See interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Digoxin.  Management: Measure digoxin serum concentrations before initiating treatment with these P-glycoprotein (P-gp) inhibitors. Reduce digoxin concentrations by either reducing the digoxin dose by 15% to 30% or by modifying the dosing frequency.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Liposomal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide Phosphate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Larotrectinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin tablets with P-glycoprotein/ABCB1 inhibitors. If concomitant use is required, monitor for lefamulin adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morphine (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Morphine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Nadolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ranolazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix.  Management: Avoid coadministration of relugolix with oral P-gp inhibitors whenever possible. If combined, take relugolix at least 6 hours prior to the P-gp inhibitor and monitor patients more frequently for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix, Estradiol, and Norethindrone: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix, Estradiol, and Norethindrone.  Management: Avoid use of relugolix/estradiol/norethindrone with P-glycoprotein (P-gp) inhibitors. If concomitant use is unavoidable, relugolix/estradiol/norethindrone should be administered at least 6 hours before the P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rimegepant.  Management: Avoid administration of another dose of rimegepant within 48 hours if given concomitantly with a P-glycoprotein (P-gp) inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RomiDEPsin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RomiDEPsin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Conventional).  Management: Avoid concurrent use of sirolimus with P-glycoprotein (P-gp) inhibitors when possible and alternative agents with lesser interaction potential with sirolimus should be considered. Monitor for increased sirolimus concentrations/toxicity if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Protein Bound). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talazoparib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Talazoparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tegaserod (Withdrawn from US Market): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tegaserod (Withdrawn from US Market). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teniposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Teniposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Disoproxil Fumarate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 50 mg and second dose (at least 2 hours later if needed) of 50 mg when used with a P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring concomitant treatment with P-glycoprotein (P-gp) inhibitors. Resume the previous venetoclax dose 2 to 3 days after discontinuation of a P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F55487471"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to use in patients who may become pregnant. Patients who may become pregnant should use effective contraception during therapy and for at least 1 week after the last dose of tepotinib. Patients with partners who may become pregnant should also use effective contraception during therapy and for 1 week after the last tepotinib dose.</p></div>
<div class="block pri drugH1Div" id="F55487472"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to tepotinib may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F55487473"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if tepotinib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Breastfeeding is not recommended by the manufacturer during therapy and for 1 week after the last tepotinib dose.</p></div>
<div class="block mop drugH1Div" id="F55487497"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Mesenchymal-epithelial transition (MET) exon 14 skipping alterations status (in tumor specimen [preferred] or plasma). Monitor LFTs (ALT, AST, and total bilirubin) at baseline, every 2 weeks during the first 3 months of treatment, then once a month or as clinically indicated; monitor more frequently if transaminases or bilirubin are elevated. Evaluate pregnancy status prior to use in patients who may become pregnant. Monitor for new or worsening pulmonary symptoms indicative of interstitial lung disease/pneumonitis (eg, dyspnea, cough, fever). Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F55487478"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Tepotinib is a receptor tyrosine kinase inhibitor that selectively targets mesenchymal-epithelial transition (MET), including the mutant variant produced by exon 14 skipping (Paik 2020). Tepotinib inhibits hepatocyte growth factor–dependent and –independent MET phosphorylation as well as MET-dependent downstream signaling pathways, which inhibits tumor cell proliferation, anchorage-independent growth, and metastases of MET-dependent tumor cells.</p></div>
<div class="block phk drugH1Div" id="F55487479"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: The tepotinib mean AUC<sub>0-inf</sub> and C<sub>max</sub> increased by 1.6-fold and by 2-fold, respectively, after administration of a high-fat, high-calorie meal (~800 to 1,000 calories; 150 calories from protein, 250 calories from carbohydrate, and 500 to 600 calories from fat).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 1,038 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 98%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily via CYP3A4 and CYP2C8; M506 is the major circulating metabolite.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 71.6% (in a fed state).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 32 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Median: 8 hours (range: 6 to 12 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces: ~85% (45% as unchanged drug); urine: ~14% (7% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 23.8 L/hour.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56522299"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Tepmetko</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Tepmetko</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Tepmetko</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Tepmetko</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Tepmetko</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Tepmetko</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Tepmetko</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Tepmetko</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Tepmetko</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Tepmetko</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Tepmetko</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Tepmetko</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Tepmetko</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Tepmetko</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Tepmetko</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Tepmetko</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Tepmetko</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Tepmetko</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Tepmetko</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference">
                  Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tepotinib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32469185">
<a name="32469185"></a>Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with <i>MET</i> exon 14 skipping mutations. <i>N Engl J Med</i>. 2020;383(10):931-943. doi:10.1056/NEJMoa2004407<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tepotinib-drug-information/abstract-text/32469185/pubmed" id="32469185" target="_blank">32469185</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Tepmetko (tepotinib) [prescribing information]. Rockland, MA: EMD Serono Inc; March 2023.</div>
</li>
<li>
<div class="reference">
                  Tepmetko (tepotinib) [product monograph]. Mississauga, Ontario, Canada: EMD Serono; May 2021.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed February 5, 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 130698 Version 46.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
